Downregulation of PMCA2 increases the vulnerability of midbrain neurons to mitochondrial complex I inhibition

NeuroToxicology

Volumn 40, Issue , 2014, Pages 43-51

  Brendel, Alexander ^a   Renziehausen, Jana ^a   Behl, Christian ^a   Hajieva, Parvana ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Calcium; Midbrain neurons; MPTP; Neuronal vulnerability; Parkinson's disease; PMCA2

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PLASMA MEMBRANE CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SMALL INTERFERING RNA; SODIUM CALCIUM EXCHANGE PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN REGION; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCEPHALON; MOLECULAR MODEL; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

CALCIUM; MIDBRAIN NEURONS; MPTP; NEURONAL VULNERABILITY; PARKINSON'S DISEASE; PMCA2;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CALCIUM; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOWN-REGULATION; ELECTRON TRANSPORT COMPLEX I; HUMANS; MALE; MESENCEPHALON; NEURONS; PLASMA MEMBRANE CALCIUM-TRANSPORTING ATPASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84890203727     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2013.11.003     Document Type: Article

References (40)

1. Beal M.F. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001, 2:325-334.
2. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003, 991:120-131.
3. Behl C., Moosmann B. Oxidative nerve cell death in Alzheimer's disease and strock: antioxidants as neuroprotective compounds. Biol Chem 2002, 383:521-536.
4. Bengtson C.P., Bading H. Nuclear calcium signaling. Adv Exp Med Biol 2012, 970:377-405.
5. Berridge M.J. Unlocking the secrets of cell signaling. Annu Rev Physiol 2005, 67:1-21.
6. Brini M. Plasma membrane Ca(2+)-ATPase: from a housekeeping function to a versatile signaling role. Pflugers Arch 2009, 457(3):657-664.
7. Brini M., Carafoli E. Calcium pumps in health and disease. Physiol Rev 2009, 89(4):1341-1378.
8. Blum D., Torch S., Lamberg N., Nissou M., Benabid A.L., Sadoul R., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001, 65(October (2)):135-172.
9. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447(7148):1081-1086.
10. Cooper-Knock J., Kirby J., Ferraiuolo L., Heath P.R., Rattray M., Shaw P.J. Gene expression profiling in human neurodegenerative disease. Nat Rev Neurol 2012, 8(9):518-530.
11. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci 2011, 12(6):359-366.
12. Dalby B., Cates S., Harris A., Ohki E.C., Tilkins M.L., Price P.J., et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 2004, 33(June (2)):95-103.
13. 2+ ATPase of animal cells: structure, function and regulation. Arch Biochem Biophys 2008, 476:65-74.
14. 2+ homeostasis and cell viability. J Neurochem 2007, 102:454-465.
15. Gamerdinger M., Manthey D., Behl C. Oestrogen receptor subtype-specific repression of calpain expression and calpain enzymatic activity in neuronal cells - implications for neuroprotection against Ca-mediated excitotoxicity. J Neurochem 2006, 97(1):57-68.
16. Gonzalez G.A., Montminy M.R. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989, 59(4):675-680.
17. Hagiwara M., Brindle P., Harootunian A., Armstrong R., Rivier J., Vale W., et al. Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol Cell Biol 1993, 13(8):4852-4859.
18. Hajieva P., Kuhlmann C., Luhmann H.J., Behl C. Impaired calcium homeostasis in aged hippocampal neurons. Neurosci Lett 2009, 451(2):119-123.
19. Hajieva P., Mocko J.B., Moosmann B., Behl C. Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity. J Neurochem 2009, 110(1):118-132.
20. Ilijic E., Guzman J.N., Surmeier D.J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 2011, 43:364-371.
21. 2+ imaging in C. elegans. Methods Mol Biol 2006, 351:253-264.
22. Kurnellas M.P., Nicot A., Shull G.E., Elkabes S. Plasma membrane calcium ATPase deficiency causes neuronal pathology in the spinal cord: a potential mechanism for neurodegeneration in multiple sclerosis and spinal cord injury. FASEB J 2005, 19:298-300.
23. Kurnellas M.P., Li H., Jain M.R., Giraud S.N., Nicot A.B., Ratnayake A., et al. Reduced expression of plasma membrane calcium ATPase 2 and collapsin response mediator protein 1 promotes death of spinal cord neurons. Cell Death Differ 2010, 17(9):1501-1510.
24. 2+ exchanger isoforms. J Biol Chem 1994, 269:14849-14852.
25. 2+ in 1-methyl-4-phenylpyridinium- or 6-hydroxydopamine-induced cell viability loss in PC12 cells. Neurochem Res 2006, 31:851-860.
26. 2+-ATPase in Alzheimer's disease. Biochem Soc Trans 2011, 39(3):819-822.
27. Mata A.M., Sepúlveda M.R. Calcium pumps in the central nervous system. Brain Res Rev 2005, 49(2):398-405.
28. Mattson M.P. Calcium and neurodegeneration. Aging Cell 2007, 6(3):337-350.
29. Montminy M. Transcriptional regulation by cyclic AMP. Annu Rev Biochem 1997, 66:807-822.
30. 2+ by circularly permuted yellow fluorescent proteins. PNAS 2004, 101:10554-10559.
31. ©) for group-wise comparison and statistical analysis of relative expression results in realtime PCR. Nucl Acids Res 2002, 30:e36.
32. Raza M., Deshpande L.S., Blair R.E., Carter D.S., Sombati S., DeLorenzo R.J. Aging is associated with elevated intracellular calcium levels and altered calcium honicostatic mechanisms in hippocampal neurons. Neurosci Lett 2007, 418:77-81.
33. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003, 23:10756-10764.
34. +). J Appl Toxicol 2009, 29:84-89.
35. Toescu E.C., Verkhratsky A. The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell 2007, 6(3):267-273.
36. Woods N.K., Padmanabhan J. Neuronal calcium signaling and Alzheimer's disease. Adv Exp Med Biol 2012, 740:1193-1217.
37. Yang L., Calingasan N.Y., Lorenzo B.J., Beal M.F. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol 2008, 211:311-314.
38. Zaidi A., Fernandes D., Bean J.L., Michaelis M.L. Effects of paraquat-induced oxidative stress on the neuronal plasma membrane Ca(2+)-ATPase. Free Radic Biol Med 2009, 47(10):1507-1514.
39. 2+-ATPase in F344/BNF1 rats. Neurobiol Aging 1998, 19(5):487-495.
40. Zhang X., Odom D.T., Koo S-H., Conkright M.D., Canettieri G., Best J., et al. Genome-wide analysis of cAMPresponse element binding protein occupancy, phosphorylation, and target gene activation in human tissues. PNAS 2005, 102:4459-4464.